Lundbeck behind the first EU-approved intravenous migraine treatment

The European Commission has decided to approve the drug Vyepti (eptinezumab) for the preventive treatment of migraines in adults who have at least four migraine attacks per month.

The announcement was expected, as the European Medicines Agency’s Expert Committee on Medicinal Products for Human Use, CHMP, issued a favourable statement in November last year, recommending that the medicinal product be approved The treatment has already been approved in the USA and several other countries, for example, Australia, Canada and Switzerland.